Vista is a start-up company founded by Spencer Farr, Ph.D (Founder Xenometrix, Phase-1), and Charles Lieber (Professor. of Chemistry, Harvard). Vista has broad, world-wide exclusive rights from Nanosys, Inc. and Harvard University for use of nanowires and nanostructures in biomedicine and drug discovery. Vista’s nanowire technology provides label-free, continuous and simultaneous measurement of biomolecules in urine, serum, tissues and tissue culture at picomolar concentrations. Vista has also obtained world-wide exclusive rights for core patents to detect and treat wet and dry forms of age-related macular degeneration (AMD).
Vista’s launch capitalizes on powerful combination of technology, people, institutions and timing:
| • | Broad, controlling, issued patents in key nanotechnology areas. |
| • | Proprietary sets of biomarkers for different classes of organ damage in animals or humans. |
| • | Large proprietary referential data set and software. |
| • | World leaders in nanotechnology, toxicology, drug development, biomarkers, internal medicine and ophthalmology. |
| • | Harvard’s backing in all areas related to nanotechnology, biomarkers and toxicology. |
| • | Extensive experience in the business in nanotechnology, drug safety assessment and assay commercialization. |
| • | Customer list of 12,000 pre-clinical and clinical scientists. |
| • | Immediate access to well-equipped and staffed wet labs. |
